IL249959A0 - Anticancer compounds that inhibit ral gtpase and methods of use - Google Patents
Anticancer compounds that inhibit ral gtpase and methods of useInfo
- Publication number
- IL249959A0 IL249959A0 IL249959A IL24995917A IL249959A0 IL 249959 A0 IL249959 A0 IL 249959A0 IL 249959 A IL249959 A IL 249959A IL 24995917 A IL24995917 A IL 24995917A IL 249959 A0 IL249959 A0 IL 249959A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- same
- cancer compounds
- compounds target
- ral gtpases
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022946P | 2014-07-10 | 2014-07-10 | |
| PCT/US2015/040021 WO2016007905A1 (en) | 2014-07-10 | 2015-07-10 | Anti-cancer compounds target ral gtpases and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL249959A0 true IL249959A0 (en) | 2017-03-30 |
Family
ID=55064987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL249959A IL249959A0 (en) | 2014-07-10 | 2017-01-06 | Anticancer compounds that inhibit ral gtpase and methods of use |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10202397B2 (enExample) |
| EP (2) | EP3686202A1 (enExample) |
| JP (2) | JP6672255B2 (enExample) |
| KR (3) | KR20170018084A (enExample) |
| CN (1) | CN106604731B (enExample) |
| AU (2) | AU2015287567A1 (enExample) |
| CA (1) | CA2954560C (enExample) |
| IL (1) | IL249959A0 (enExample) |
| WO (1) | WO2016007905A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016007905A1 (en) | 2014-07-10 | 2016-01-14 | The Regents Of The University Of Colorado, A Body Corporate | Anti-cancer compounds target ral gtpases and methods of using the same |
| US10646475B2 (en) | 2015-03-10 | 2020-05-12 | The Trustees Of Princeton University | SHMT inhibitors |
| US10077273B2 (en) | 2016-09-14 | 2018-09-18 | The Trustees Of Princeton University | SHMT inhibitors |
| CN109305972B (zh) * | 2018-09-27 | 2021-07-09 | 广州医科大学 | 一种二氢吡喃并吡唑类化合物及其制备方法和应用 |
| EP3766544A1 (en) * | 2019-07-18 | 2021-01-20 | Centre Hospitalier Regional Universitaire de Lille | Novel pyrazolone derivatives as pd-1/pd-l1 interaction inhibitors |
| CA3199138A1 (en) * | 2020-11-18 | 2022-05-27 | Texas Tech University System | Therapies for cancer using small molecules that bind to and inhibit ral interacting proteins |
| CN114765064A (zh) * | 2021-01-14 | 2022-07-19 | 南京天顶星医药科技有限公司 | 一种靶向RalA-GDP蛋白的药物的虚拟筛选方法 |
| AU2022272475A1 (en) | 2021-05-10 | 2023-10-05 | Novalum S.a. | Cathode current collector bar of an aluminium production cell |
| CN114632147B (zh) * | 2021-11-09 | 2024-04-30 | 南京大学 | 人类受试者心肌病的治疗 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4555396A (en) | 1982-12-22 | 1985-11-26 | Eastman Kodak Company | Use of pyrylium and thiapyrylium compounds as biological stains |
| US5750550A (en) | 1995-09-15 | 1998-05-12 | Sanofi | 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof |
| JPH10279480A (ja) | 1997-04-07 | 1998-10-20 | Mitsubishi Chem Corp | 皮膚組織障害の予防・治療剤 |
| US6143471A (en) | 1998-03-10 | 2000-11-07 | Mitsubishi Paper Mills Limited | Positive type photosensitive composition |
| WO2000040749A2 (en) | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| WO2005020784A2 (en) * | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| CA2533803A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| KR20080015123A (ko) | 2005-05-25 | 2008-02-18 | 다나베 미츠비시 세이야꾸 가부시키가이샤 | 피라졸론 유도체를 포함하는 의약 |
| US7826982B2 (en) | 2005-07-29 | 2010-11-02 | Children's Hospital Medical Center | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE |
| KR20080040032A (ko) | 2005-09-02 | 2008-05-07 | 티보텍 파마슈티칼즈 리미티드 | Ｈｃｖ 저해제로서의 벤조디아제핀 |
| EP1957474A4 (en) | 2005-11-04 | 2011-08-24 | Harvard College | SYNTHESIS OF FTSZ HEMMERN |
| US20070203224A1 (en) | 2006-01-09 | 2007-08-30 | University Of Southern California | Small-molecules for treating cancer and abnormal cell proliferation disorders |
| WO2008143894A2 (en) | 2007-05-14 | 2008-11-27 | Dana-Farber Cancer Institute, Inc. | Phosphorylated rala |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2011010715A1 (ja) * | 2009-07-24 | 2011-01-27 | 国立大学法人 東京大学 | Ｐr－Ｓｅｔ７阻害剤 |
| WO2011035143A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Methods and compositions for inhibiting rho-mediated diseases and conditions |
| US8673913B2 (en) * | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| US20120214824A1 (en) | 2010-12-08 | 2012-08-23 | Bradley Tait | Proteostasis regulators |
| US9200046B2 (en) * | 2011-06-29 | 2015-12-01 | Cornell University | Reporter system for high throughput screening of compounds and uses thereof |
| EP2793881B1 (en) * | 2011-12-21 | 2018-10-31 | The Regents of the University of Colorado | Anti-cancer compounds targeting ral gtpase |
| US20150011411A1 (en) | 2011-12-21 | 2015-01-08 | THE REGENTS OF THE UNIVERSITY OF COLORADO a body corporation | Biomarkers of cancer |
| WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| WO2013182472A1 (en) * | 2012-06-06 | 2013-12-12 | Basf Se | Pyrazolopyrans having herbicidal and pharmaceutical properties |
| CN103910737B (zh) * | 2014-03-25 | 2016-08-17 | 浙江师范大学 | 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用 |
| WO2016007905A1 (en) * | 2014-07-10 | 2016-01-14 | The Regents Of The University Of Colorado, A Body Corporate | Anti-cancer compounds target ral gtpases and methods of using the same |
| WO2016205460A1 (en) * | 2015-06-16 | 2016-12-22 | Nantbioscience, Inc. | Polycyclic derivatives targeting ral gtpases and their therapeutical applications |
-
2015
- 2015-07-10 WO PCT/US2015/040021 patent/WO2016007905A1/en not_active Ceased
- 2015-07-10 CA CA2954560A patent/CA2954560C/en active Active
- 2015-07-10 EP EP20162079.6A patent/EP3686202A1/en not_active Withdrawn
- 2015-07-10 KR KR1020177002960A patent/KR20170018084A/ko not_active Ceased
- 2015-07-10 AU AU2015287567A patent/AU2015287567A1/en not_active Abandoned
- 2015-07-10 US US15/324,629 patent/US10202397B2/en not_active Ceased
- 2015-07-10 CN CN201580047117.8A patent/CN106604731B/zh not_active Expired - Fee Related
- 2015-07-10 KR KR1020207008228A patent/KR20200034824A/ko not_active Ceased
- 2015-07-10 KR KR1020197005669A patent/KR102093848B1/ko active Active
- 2015-07-10 EP EP15819681.6A patent/EP3166609B1/en active Active
- 2015-07-10 JP JP2017500822A patent/JP6672255B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-06 IL IL249959A patent/IL249959A0/en unknown
-
2019
- 2019-01-07 US US16/241,587 patent/US10676480B2/en active Active
- 2019-08-27 US US16/553,092 patent/USRE48557E1/en active Active
-
2020
- 2020-03-04 JP JP2020036345A patent/JP7102012B2/ja active Active
- 2020-04-30 US US16/863,867 patent/US11472812B2/en active Active
- 2020-11-27 AU AU2020277293A patent/AU2020277293B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015287567A1 (en) | 2017-02-16 |
| JP2017520588A (ja) | 2017-07-27 |
| JP6672255B2 (ja) | 2020-03-25 |
| KR20170018084A (ko) | 2017-02-15 |
| JP7102012B2 (ja) | 2022-07-19 |
| CN106604731A (zh) | 2017-04-26 |
| US20170204112A1 (en) | 2017-07-20 |
| WO2016007905A1 (en) | 2016-01-14 |
| US11472812B2 (en) | 2022-10-18 |
| EP3686202A1 (en) | 2020-07-29 |
| EP3166609B1 (en) | 2020-03-11 |
| CA2954560C (en) | 2021-12-28 |
| USRE48557E1 (en) | 2021-05-18 |
| KR20200034824A (ko) | 2020-03-31 |
| EP3166609A4 (en) | 2017-12-27 |
| AU2020277293A1 (en) | 2021-01-07 |
| EP3166609A1 (en) | 2017-05-17 |
| CA2954560A1 (en) | 2016-01-14 |
| JP2020105195A (ja) | 2020-07-09 |
| KR102093848B1 (ko) | 2020-03-30 |
| CN106604731B (zh) | 2021-05-18 |
| AU2020277293B2 (en) | 2021-10-21 |
| US10676480B2 (en) | 2020-06-09 |
| KR20190022929A (ko) | 2019-03-06 |
| US10202397B2 (en) | 2019-02-12 |
| US20190135824A1 (en) | 2019-05-09 |
| US20200255442A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| IL252532A0 (en) | Polycyclic carbamoylpyridone compounds and their pharmaceutical use | |
| IL258768A (en) | Compounds interacting with glycans and methods of use | |
| IL254552A0 (en) | Polycyclic carbamoylpyridone compounds and their pharmaceutical uses | |
| SI3215147T1 (sl) | Nevroatenuacijske spojine norketamina in postopki | |
| SG11201706029VA (en) | Anti-senescence compounds and uses thereof | |
| IL249959A0 (en) | Anticancer compounds that inhibit ral gtpase and methods of use | |
| IL251107A0 (en) | Compounds and methods | |
| ZA201705456B (en) | Benzoxaborole compounds and uses thereof | |
| IL247325A0 (en) | Therapeutic methods using noribogaine and related compounds | |
| GB201608779D0 (en) | Methods and compounds | |
| ZA201702901B (en) | Stabilized adrenomedullin derivatives and use thereof | |
| GB201608776D0 (en) | Methods and compounds | |
| ZA201606450B (en) | Compounds and their methods of use | |
| PL3234386T3 (pl) | Element ślizgowy i sposób jego wytwarzania | |
| GB201517786D0 (en) | Methods and materials | |
| IL253459B (en) | Isoergoline compounds and their uses | |
| GB201718875D0 (en) | Autophagy-inhibiting compounds and uses thereof | |
| ZA201607353B (en) | Bicyclic derivatives and pharmaceutical composition including the same | |
| GB2543375B (en) | Compounds and their uses | |
| GB201514770D0 (en) | Compounds and their use | |
| GB201602169D0 (en) | Fasteners | |
| GB201513318D0 (en) | Novel compounds and their use |